Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D 

Research output: Contribution to journalJournal articlepeer-review

  • Andrea Morales Caceres
  • Kshitij Kumar Singh
  • Minssen, Timo
  • Steven J. Hoffman
  • Susan Rogers Van Katwyk
The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.
Original languageEnglish
JournalJournal of Law, Medicine & Ethics
Volume50
Issue numberS2 (Winter 2022)
Pages (from-to)47-54
Number of pages8
ISSN1073-1105
DOIs
Publication statusPublished - 2022

ID: 312845009